Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ t2 v0 a: c$ d0 m/ uNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
* _. V8 d. Y3 ]' S$ q+ Author Affiliations
# f7 j1 j7 d3 k% _4 w0 w) T# B
: i; d5 c: Z3 d! s1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
" x9 G( G& K& z/ n2 W2 s+ n2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan D0 h+ _ p5 x: c, i" H
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 0 ?9 Z- T- K$ q& I8 R
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) \( E9 {( ?) `! Y$ C& A
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. I& d) L, R s6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
3 l( _% ?7 m5 O4 ]2 P# d3 r$ \. u7Kinki University School of Medicine, Osaka 589-8511, Japan 5 ^6 {3 U+ P0 _; N" I9 N& u2 {
8Izumi Municipal Hospital, Osaka 594-0071, Japan
2 P' v" n5 l, u1 W9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
* }$ g6 u8 k8 p5 ]/ A% I6 rCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
$ i4 O& Y* d8 I7 m! d4 R) J( fAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 4 Q* t6 p( o6 u" m9 z
7 d" W" e. ~+ G+ j+ g0 M
|